Review the side-effects of Aztreonam as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
Vol. 7, Supplement 4. Gram-Negative Aerobic Bacterial Infections: A Focus on Directed Therapy, with Special Reference to Aztreonam (Nov. - Dec., 1985), pp. S741-S746 (6 pages) Aztreonam plus ...
Aztreonam (Azactam (2000 mg)) is monobactam antibiotic, prescribed for serious infections caused by susceptible gram negative bacteria like urinary tract infection, lower respiratory tract infection.
A comparison of aztreonam and tobramycin was carried out in 49 hospitalized patients with lower respiratory tract infections caused by gram-negative bacilli. Patients were randomly assigned to the ...
The Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to ATM-AVI (aztreonam and avibactam; Allergan) for the treatment ...
Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis Data Presented at Cystic Fibrosis Therapeutics Development Network ...
FOSTER CITY, Calif., Dec 10, 2009 (BUSINESS WIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA ...
Am J Health Syst Pharm. 2012;69(2):107-115. Kristen Zeitler, Pharm.D., is Postgraduate Year 1 Pharmacy Practice Resident, Hospital of the University of Pennsylvania, Philadelphia; at the time of ...
Gilead Sciences has moved a step closer to getting approval for its cystic fibrosis treatment in the USA. Gilead Sciences has moved a step closer to getting approval for its cystic fibrosis treatment ...
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Patients with CF often require long-term antibiotic therapy for recurrent lung infections, which may increase the likelihood of antimicrobial resistance. To date, no clinical trial has specifically ...